The use of either a selective or a non-selective nonsteroidal antiinflammatory drug for the treatment of Alzheimer’s disease (AD) has no effect on cognitive or behavioral function over a period of 12 months, according to the results of a multicenter trial presented here this week at the 8th International Conference on Alzheimer’s Disease and Related Disorders.
Dr. Paul Aisen of Georgetown University Medical Center in Washington, DC, and colleagues randomized 351 patients with mild to moderate AD to rofecoxib, 25 mg a day; naproxen, 200 mg, twice a day; or placebo. The majority of patients in the study were taking an acetylcholinesterase inhibitor, and both vitamin E and low-dose aspirin were allowed.
The primary outcome measure was change in cognition from baseline at 12 months, as measured by the cognitive sub-scale of the Alzheimer’s Disease Assessment Scale (ADAScog) and other instruments. Secondary outcome measures included changes in activities of daily living and time to first endpoint, which included decline in test scores, institutionalization and death.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!